← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Apeiron Investment Group Ltd.
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001845711
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 6
- Purchases · 24M
- 9
- Average purchase
- $6.1M
- Median purchase
- $2.5M
- Gross purchase value
- $55.3M
Companies: ATAI Life Sciences N.V. | Enhanced Group Inc.
9 SEC accession(s) · 9 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-09-21 | Enhanced Group Inc. | ENHA | Director | 10% Owner | $7.0M | Open filing |
| 2026-09-09 | Enhanced Group Inc. | ENHA | Director | 10% Owner | $286.0K | Open filing |
| 2026-09-04 | Enhanced Group Inc. | ENHA | Director | 10% Owner | $210.3K | Open filing |
| 2026-08-20 | Enhanced Group Inc. | ENHA | Director | 10% Owner | $2.9M | Open filing |
| 2026-08-18 | Enhanced Group Inc. | ENHA | Director | 10% Owner | $330.0K | Open filing |
| 2026-08-17 | Enhanced Group Inc. | ENHA | Director | 10% Owner | $295.5K | Open filing |
| 2025-08-18 | ATAI Life Sciences N.V. | ATAI | 10% Owner | $19.0M | Open filing |
| 2025-03-24 | ATAI Life Sciences N.V. | ATAI | 10% Owner | $2.5M | Open filing |
| 2025-02-19 | ATAI Life Sciences N.V. | ATAI | 10% Owner | $22.8M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 1/8
- Large purchase ≥ $100k
- 9/9
- Cluster buying · 15D
- 9/9
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.